drugset
drugset / Trial / NCT02504580

Pilot Herniorrhaphy Study for Postoperative Analgesia

NCT02504580 ↗

Phase 2 Completed 463 enrolled Heron Therapeutics
RandomizedFactorialDouble-blindPrevention

Summary

A Phase 2, Randomized, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy

Timeline

Start
2015-07
Primary completion
2017-03
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine HCI Unknown 75 mg Other
Subject HTX-002 Unknown 200 mg Other
Subject HTX-002 Unknown 400 mg Other
Subject HTX-009 Unknown 12 mg Other
Subject HTX-011 Unknown 200 mg Other
Subject HTX-011 Unknown 400 mg Other
Subject HTX-011A Unknown 200 mg Other
Subject HTX-011A Unknown 400 mg Other
Subject HTX-011B Unknown 200 mg Other
Subject HTX-011B Unknown 300 mg Other
Subject HTX-011B Unknown 400 mg Other

Indications

No indication recorded.